FDA product code LCP: Assay, Glycosylated Hemoglobin
LCP is the FDA product code for assay, glycosylated hemoglobin. It is a Class II device, regulated under 21 CFR 864.7470 and reviewed by the Hematology panel. FDA has cleared 249 510(k) submissions under LCP, 3 in the last five years, from 118 different applicants. The average 510(k) review took 146 days (median 100); 931 days on average over the last three years. FDA has posted 103 recalls for LCP devices, 6 initiated in the last five years.
Classification
| Field | Value |
|---|---|
| Device name | Assay, Glycosylated Hemoglobin |
| Device class | Class II |
| Regulation | 21 CFR 864.7470 |
| Review panel | HE — Hematology |
| Medical specialty | Hematology |
| Premarket route | 510(k) |
510(k) clearances per year for LCP
| Year | Clearances | Avg. review days |
|---|---|---|
| 2017 | 5 | 244 |
| 2018 | 2 | 362 |
| 2019 | 4 | 238 |
| 2020 | 1 | 153 |
| 2023 | 2 | 418 |
| 2024 | 1 | 931 |
Compare with all 510(k) review times · Search every LCP clearance
Top LCP applicants
| Applicant | Clearances | Latest |
|---|---|---|
| Helena Laboratories | 19 | 1995-07-11 |
| Bio-Rad | 15 | 2000-12-19 |
| Bio-Rad Laboratories, Inc. | 8 | 2014-06-25 |
| Metrika, Inc. | 7 | 2005-06-13 |
| Abbott Laboratories | 7 | 2000-05-25 |
113 more applicants have LCP clearances. See the full list in Caduvo.
Most recent LCP clearances
| 510(k) | Applicant | Device | Decision date | Review days |
|---|---|---|---|---|
| K221326 | Nova Biomedical Corporation | Nova Allegro HbA1c Assay, Nova Allegro Analyzer | 2024-11-22 | 931 |
| K231465 | Qurasense | Q-Pad Test System | 2023-12-06 | 201 |
| K214117 | Abbott Diagnostics Technologies AS | Afinion HbA1c, Afinion 2 and Alere Afinion AS100 Analyzer | 2023-09-27 | 636 |
| K192987 | Jana Care, Inc. | Aina HbA1c Monitoring System 2 | 2020-03-26 | 153 |
| K192369 | Ixensor Co, Ltd. | PixoTest POCT System - PixoTest POCT Analyzer and PixoTest A1c Test Kit | 2019-10-29 | 60 |
Recalls for LCP devices
103 product recalls in 48 recall events; 6 initiated in the last five years and 5 still open. Most recent: 2025-11-03.
| Year | Recalls |
|---|---|
| 2017 | 1 |
| 2018 | 4 |
| 2020 | 3 |
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 2 |
Frequently asked questions
What is FDA product code LCP?
LCP is the FDA product code for assay, glycosylated hemoglobin. It is a Class II device, regulated under 21 CFR 864.7470 and reviewed by the Hematology panel.
What device class is LCP?
Class II, regulation 21 CFR 864.7470. Typical premarket route: 510(k).
How long does a 510(k) take for product code LCP?
Across 249 cleared submissions the average was 146 days from receipt to decision (median 100).
Which companies have the most LCP clearances?
Helena Laboratories (19); Bio-Rad (15); Bio-Rad Laboratories, Inc. (8); Metrika, Inc. (7); Abbott Laboratories (7).
Have LCP devices been recalled?
Yes: 103 product recalls across 48 recall events; the most recent began 2025-11-03.
Next steps
- Run an FDA pathway report with predicate devices for product code LCP
- Run a recall and safety report across every LCP manufacturer
- Watch product code LCP for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Hematology product codes · FDA product code lookup · 510(k) database search · 510(k) review times